We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surveillance Cohort Long-Term Toxicity Antiretrovirals in HIV-Infected Patients Enrolled in TPV Cohort

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00805857
First Posted: December 10, 2008
Last Update Posted: December 10, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Boehringer Ingelheim
June 10, 2008
December 10, 2008
December 10, 2008
June 2008
December 2009   (Final data collection date for primary outcome measure)
To evaluate the prevalence and incidence of serious adverse events and serious unexpected adverse events in HIV infected patients enrolled in Tipranavir cohort and to identify possible risk factors [ Time Frame: 48wks ]
Same as current
No Changes Posted
the evaluation of tipranavir containing regimens durability, considering treatment interruption for each reason [ Time Frame: 48wks ]
Same as current
Not Provided
Not Provided
 
Surveillance Cohort Long-Term Toxicity Antiretrovirals in HIV-Infected Patients Enrolled in TPV Cohort
SCOLTA: SURVEILLANCE COHORT LONG-TERM TOXICITY ANTIRETROVIRALS

The SCOLTA project is a system for online surveying of adverse events to recently commercialized antiretroviral drugs and a sentinel for unexpected and late adverse events reactions arising during any antiretroviral treatment.Aim of the proposed study is:

  1. to evaluate the prevalence and incidence of serious adverse events and serious unexpected adverse events in HIV-infected patients enrolled in the SCOLTA project Tipranavir cohort and to identify possible risk factors
  2. the evaluation of tipranavir containing regimens durability, considering treatment interruption for each reason.
Not Provided
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
HIV Infections
Drug: Tipranavir
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
150
Not Provided
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients > 18 years old HIV infected treated with tipranavir

Exclusion Criteria:

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00805857
1182.144
Not Provided
Not Provided
Not Provided
Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
December 2008